Home Cart Sign in  
Chemical Structure| 459147-39-8 Chemical Structure| 459147-39-8

Structure of SW033291
CAS No.: 459147-39-8

Chemical Structure| 459147-39-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SW033291 selectively inhibit 15-PGDH with IC50 and Kiapp values of 1.5 nM and 0.1 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SW033291

CAS No. :459147-39-8
Formula : C21H20N2OS3
M.W : 412.59
SMILES Code : NC1=C(S(CCCC)=O)SC2=NC(C3=CC=CS3)=CC(C4=CC=CC=C4)=C21
MDL No. :MFCD02973087
InChI Key :LCYAYKSMOVLVRL-UHFFFAOYSA-N
Pubchem ID :3337839

Safety of SW033291

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

    15-PGDH, Ki:0.1 nM

    15-PGDH, IC50:1.5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 500 nM Inhibited RSK4 activation, resulting in decreased cellular cIAP1 and cIAP2 expression PMC4481126
A549 cells 20 nM 8 hours Inhibited RSK4 activation, resulting in decreased cellular cIAP1 and cIAP2 expression PMC5580352
A549 cells 10 nM Inhibited RSK4 activation, resulting in decreased cellular cIAP1 and cIAP2 expression PMC6058768

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Bone marrow transplant model, colitis model, and liver injury model Intraperitoneal injection 10 mg/kg Twice daily for 21 days To evaluate the promotion of tissue regeneration by SW033291, results showed accelerated hematopoietic recovery after bone marrow transplant and promoted tissue regeneration after colon and liver injury PMC4481126
Mice EP4 knockout mice Injection 10 mg/kg/day Once daily for 7 days To evaluate the effect of SW033291 on bone regeneration, results showed significant promotion of bone formation in EP4wt mice, but the effect was obstructed in EP4 knockout mice PMC6331599
Mice Bone marrow transplantation, ulcerative colitis, and partial hepatectomy models Intraperitoneal injection 10 mg/kg Single dose To evaluate the effect of SW033291 on PGE2 levels in vivo, results showed that PGE2 levels doubled in bone marrow, colon, lung, and liver at 3 hours post-dose. PMC5580352
Mice WT and EP4Avil–/– mice Injection 10 mg/kg/d Daily for 1 month SW033291 significantly increased the number of osteoblasts and decreased the number of adipocytes in WT mice, and these effects were absent in EP4Avil–/– mice. PMC7324175
Mice Bone marrow transplantation model Intraperitoneal injection 5 mg/kg Twice daily for 5 days PGDHi, by inhibiting 15-PGDH, increases PGE2 levels in the spleen and bone marrow, promotes homing and regeneration of hematopoietic stem cells, and accelerates hematopoietic recovery after bone marrow transplantation. PMC8026178
Mice Bone marrow transplant model Intraperitoneal injection 5 mg/kg Twice daily for 12 days Accelerate hematopoietic recovery PMC6058768
Mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 5 mg/kg Twice daily for 35 days To evaluate the protective effects of 15-PGDH inhibition on pulmonary fibrosis. Results showed that PGDHi attenuated early inflammation, reduced fibrotic lesions and extracellular matrix remodeling, improved pulmonary function, and decreased mortality. PMC7363833

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.12mL

2.42mL

1.21mL

24.24mL

4.85mL

2.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories